Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk

Dow Jones

10/20

0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com)

(END) Dow Jones Newswires

October 20, 2025 04:04 ET (08:04 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2576836064"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2576836064\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2576836064?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-20 16:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2576836064","market":"hk","top_or_hot":-1,"title":"Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 04:04 ET (08:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma's Roche Deal Could Help Unlock Commercial Potential -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-10-20 16:04</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 20, 2025 04:04 ET (08:04 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2576836064","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2576836064","pubTimestamp":1760947440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1191":"制药","BK1583":"高瓴概念","03692":"翰森制药"},"translate_title":"翰森制药与罗氏的交易可能有助于释放商业潜力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"0804 GMT - Hansoh Pharmaceutical Group's new out-licensing deal with Roche could help to unlock the commercial potential of its anti-body drug conjugate, says Nomura's Jialin Zhang in a note. The deal, in which Hansoh Pharmaceutical will receive US$80 million up front, is likely to contribute up to 10% of Nomura's projected 2025 earnings estimates for the Chinese healthcare company, says Zhang. The agreement with Roche also endorses Hansoh's research and development capability, Nomura says, noting that this could contribute to making Hansoh's drug commercially-viable. Nomura raises its estimated 2026 revenue and earnings for Hansoh by 3.2% and 3.8%, respectively. The bank lifts its target price to HK$35.50 from HK$35.47 while maintaining its neutral rating on Hansoh. Shares fall 0.2% to HK$36.34. (megan.cheah@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 20, 2025 04:04 ET (08:04 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}